Figure 1: Typical Kaplan-Meier Plot for Chemotherapy, Targeted Therapy, IO, and IO Combinations
Figure 2: Timeline of All IO Products Approved
Figure 3: Development of Opdivo Across Oncology Indications
Figure 4: Timeline of Approvals/Estimated Approvals for Opdivo
Figure 5: Overview of Selected Opdivo Late-Stage Trials
Figure 6: Opdivo Sales Estimate for 2019 and 2024
Figure 7: Development of Keytruda Across Oncology Indications
Figure 8: Timeline of Approvals/Estimated Approvals for Keytruda
Figure 9: Overview of Selected Keytruda Late-Stage Trials
Figure 10: Keytruda Sales Estimate for 2019 and 2024
Figure 11: Development of Atezolizumab Across Oncology Indications
Figure 12: Timeline of Approvals/Estimated Approvals for Atezolizumab
Figure 13: Overview of Selected Atezolizumab Late-Stage Trials
Figure 14: Atezolizumab Sales Estimate for 2019 and 2024
Figure 15: Development of Durvalumab Across Oncology Indications
Figure 16: Development of Tremelimumab Across Oncology Indications
Figure 17: Timeline of Approvals/Estimated Approvals for Durvalumab (with Tremelimumab)
Figure 18: Overview of Selected Durvalumab Late-Stage Trials
Figure 19: Durvalumab Sales Estimate for 2019 and 2024
Figure 20: Tremelimumab Sales Estimate for 2019 and 2024
Figure 21: Development of Avelumab Across Oncology Indications
Figure 22: Timeline of Approvals/Estimated Approvals for Avelumab
Figure 23: Overview of Selected Avelumab Late-Stage Trials
Figure 24: Avelumab Sales Estimate for 2019 and 2024
Figure 25: Development of Yervoy Across Oncology Indications
Figure 26: Timeline of Approvals/Estimated Approvals for Yervoy
Figure 27: Overview of Selected Yervoy Late-Stage Trials
Figure 28: Yervoy Sales Estimate for 2019 and 2024
Figure 29: IO Cell Therapies Sales Estimate for 2019 and 2024
Figure 30: Cancer Vaccines Sales Estimate for 2019 and 2024
Figure 31: Oncolytic Virus Sales Estimate for 2019 and 2024
Figure 32: Bispecific T-Cell Engagers Sales Estimate for 2019 and 2024
Figure 33: Empliciti Sales Estimate for 2019 and 2024
Figure 34: Treatment Flow Chart for ALL Patients
Figure 35: Treatment Flow Chart for AML Patients
Figure 36: Overview of Main IO Approaches, Targets, and Trial Development in ALL Patients
Figure 37: Overview of Main IO Approaches, Targets, and Trial Development in AML Patients
Figure 38: Approval Timeline for IO Drugs in ALL Patients
Figure 39: An Overview of the Late-Stage Trials with IO Products in ALL Patients
Figure 40: An Overview of the Late-Stage Trials with IO Products in AML Patients
Figure 41: An Overview of the Early-Stage Trials with IO Products in ALL Patients
Figure 42: An Overview of the Early-Stage Trials with IO Products in AML Patients
Figure 43: Non-Immunotherapy Treatments in ALL Patients
Figure 44: Non-Immunotherapy Treatments in AML Patients
Figure 45: Treatment Flow Chart for Bladder Cancer Patients
Figure 46: Overview of Immuno-oncology Development in Bladder Cancer
Figure 47: Phase III Timeline in Bladder Cancer
Figure 48: Phase III Trials in Bladder Cancer
Figure 49: Overview of the Early-Stage IO Trials in Bladder Cancer Patients
Figure 50: Non-immunotherapy Threats in Bladder Cancer
Figure 51: Treatment Flow Chart for Stage 0–III Breast Cancer Patients
Figure 52: Treatment Flow Chart for Stage IV or Recurrent Breast Cancer Patients
Figure 53: Overview of IO Development in Breast Cancer
Figure 54: Current Phase III Timeline in Breast Cancer
Figure 55: Late-Stage Pivotal Trials in Breast Cancer Patients
Figure 56: Overview of the Early-Stage IO Trials in Breast Cancer Patients
Figure 57: Non-immunotherapy Threats in Breast Cancer
Figure 58: Treatment Flow Chart for CLL Patients
Figure 59: Treatment Flow Chart for CML Patients
Figure 60: Overview of Main IO Approaches, Targets, and Trial Development in CLL Patients
Figure 61: Overview of Main IO Approaches, Targets, and Trial Development in CML Patients
Figure 62: An Overview of the Late-Stage Trials with IO Products in CLL Patients
Figure 63: An Overview of the Late-Stage Trials with IO Products in CML Patients
Figure 64: An Overview of the Early-Stage Trials with IO Products in CLL Patients
Figure 65: An Overview of the Early-Stage Trials with IO Products in CML Patients
Figure 66: Non-immunotherapy Treatments in CLL Patients
Figure 67: Non-Immunotherapy Treatments in CML Patients
Figure 68: Treatment Flow Chart for CRC Patients
Figure 69: Overview of Main IO Approaches, Targets, and Trial Development in CRC Patients
Figure 70: Current Phase III and Regulatory Approval Timeline in CRC
Figure 71: An Overview of the Late-Stage Trials with IO Products in CRC Patients
Figure 72: An Overview of the Early-Stage Trials with IO Products in CRC Patients
Figure 73: Non-immunotherapy Treatments in CRC Patients
Figure 74: Treatment Flow Chart for Advanced G/GEJAC Patients
Figure 75: Overview of IO Development in G/GEJAC
Figure 76: Current Phase III Timeline in G/GEJAC
Figure 77: Late-Stage Pivotal IO Trials in G/GEJAC Patients
Figure 78: Selected Early-Stage IO Trials in G/GEJAC Patients
Figure 79: Non-immunotherapy Threats in G/GEJAC
Figure 80: Treatment Flow Chart for GBM Patients
Figure 81: Overview of Immunotherapies in Glioblastoma
Figure 82: Current Phase III Timeline in GBM
Figure 83: Late-Stage Pivotal IO Trials in GBM Patients
Figure 84: Overview of Selected Trials in GBM Patients
Figure 85: Non-immunotherapy Treatments in GBM
Figure 86: Treatment Flow Chart for HNSCC Patients
Figure 87: Overview of IO Development in HNSCC
Figure 88: Current Phase III Timeline in HNSCC
Figure 89: Late-Stage Pivotal IO Trials in HNSCC Patients
Figure 90: Overview of Early-Stage IO Trials in HNSCC Patients
Figure 91: Non-immunotherapy Threats in HNSCC
Figure 92: HCC Treatment Regimen by BCLC Stage
Figure 93: Overview of Immuno-oncology Development in HCC
Figure 94: Phase III Timeline in HCC
Figure 95: Phase III Trials in HCC
Figure 96: Overview of the Early-Stage IO Trials in HCC Patients
Figure 97: Non-immunotherapy Threats in HCC
Figure 98: Current Flowchart for Melanoma
Figure 99: Overview of IO Development in Melanoma
Figure 100:Current Phase III Timeline in Melanoma
Figure 101:Late-Stage Pivotal IO Trials in Melanoma Patients
Figure 102:Immune Checkpoint Modulator Combinations in Early-Stage Development
Figure 103:Non-immunotherapy Threats in Melanoma
Figure 104:Treatment Flow Chart for Multiple Myeloma Patients
Figure 105:Overview of Immunotherapies in Multiple Myeloma
Figure 106:Current Phase III Timeline in Multiple Myeloma
Figure 107:Late-Stage Pivotal IO Trials in Multiple Myeloma Patients
Figure 108:Selected Early-Stage Pivotal IO Trials in Multiple Myeloma Patients
Figure 109:Non-immunotherapy Treatments in Multiple Myeloma
Figure 110:Treatment Algorithm for NHL Patients
Figure 111:IO Approaches, Targets, and Clinical Trials in NHL Patients
Figure 112:Current Regulatory Approval Timeline in NHL
Figure 113:Late-Stage IO Trials in NHL Patients
Figure 114:Overview of Early-Stage IO Trials in NHL Patients
Figure 115:Non-immunotherapy Threats in NHL
Figure 116:Treatment Flow Chart for Stage III/IV NSCLC Patients
Figure 117:Overview of Main IO Approaches, Targets, and Trial Development in NSCLC Patients
Figure 118:Current Phase III Timeline in NSCLC
Figure 119:An Overview of the Late-Stage Trials with IO Products in NSCLC Patients
Figure 120:Overview of the Early-Stage IO Trials in NSCLC Patients
Figure 121:Non-immunotherapy Treatments in NSCLC
Figure 122:Top-Level Treatment Flow Chart for Ovarian Cancer Patients
Figure 123:Ovarian Cancer IO Products in Development by Therapeutic Approach
Figure 124:IO Products in Late-Stage Development for Ovarian Cancer—Estimated Approval Dates
Figure 125:IO Products in Late-Stage Development for Ovarian Cancer—Pivotal Clinical Trials
Figure 126:IO Products in Early-Stage Development for Ovarian Cancer
Figure 127:Non-IO Therapies Recently Approved or in the Late-Stage Ovarian Cancer Pipeline
Figure 128:Treatment Flow Chart for Pancreatic Cancer Patients
Figure 129:Overview of Immunotherapies in Pancreatic Cancer
Figure 130:Estimated Approval Times for Immunotherapies in Pancreatic Cancer
Figure 131:Current Phase III Trials in Pancreatic Cancer
Figure 132:Selected Early-Phase IO Trials in Pancreatic Cancer
Figure 133:Non-immunotherapy Treatments in Pancreatic Cancer
Figure 134:Treatment Flow Chart for Prostate Cancer Patients
Figure 135:Overview of Main IO Approaches, Targets, and Trial Development in Prostate Cancer Patients
Figure 136:Current Phase III and Regulatory Approval Timeline in Prostate Cancer Patients
Figure 137:An Overview of the Late-Stage Trials with IO Products in Prostate Cancer Patients
Figure 138:An Overview of the Early-Stage IO Trials in Prostate Cancer Patients
Figure 139:Non-immunotherapy Treatments in Prostate Cancer Patients
Figure 140:Treatment Algorithm for Advanced RCC Patients
Figure 141:IO Approaches, Targets, and Clinical Trials in RCC Patients
Figure 142:Current Phase III and Regulatory Approval Timeline in RCC
Figure 143:Late-Stage IO Trials in RCC Patients
Figure 144:Early-Stage IO Trials in RCC Patients
Figure 145:Non-immunotherapy Threats in RCC
Figure 146:Clinical Development Activity by Combination Type and Development Phase
Figure 147:Clinical Development Activity by Combination and Cancer Type
Figure 148:Clinical Development Activity by Combination Type and Approach
Figure 149:Clinical Development Activity by Combination Type and Target
Figure 150:Select IO Products in Clinical Development by Combination Type
Figure 151:Select Keytruda IO Combinations in Clinical Development by Combination Type
Figure 152:Select Opdivo/Yervoy Combinations in Clinical Development by Combination Type
Figure 153:Select Durvalumab/Tremelimumab IO Combinations in Clinical Development by Combination Type
Figure 154:Select Atezolizumab IO Combinations in Clinical Development by Combination Type
Figure 155:Number of Trials Tagged for PD-L1 Biomarker Positivity
Figure 156:Number of Trials Tagged for HLA-A2/A1 Positivity
Figure 157:Number of Deals by IO Products